Up 90% in 2 weeks, here's why the Paradigm share price has been halted

The biopharmaceutical company is planning a capital raise.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The Paradigm share price has been frozen today
  • The biopharmaceutical company has requested a trading halt pending a capital raising announcement
  • Paradigm has a number of research initiatives on the go

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is going nowhere today after the company requested a trading halt. 

The Paradigm share price has rocketed from $1.05 per share on 28 July to $1.99 per share at Wednesday's close, a gain of 89.5%. 

Across this timeframe, the ASX-listed biopharmaceutical company released its quarterly results for the three months ended 30 June 2022 and announced the results of a major research project.

Before market open this morning, it entered a trading halt pending an announcement relating to a capital raising.

Let's dive deeper to get up to speed with what's happening at Paradigm. 

Female doctor with a mask holds out hand in a stop gesture.

Image source: Getty Images

Why is Paradigm in a trading halt?

The Paradigm share price has been frozen today after the company requested a trading halt in relation to a capital raising.

It will remain halted until the start of normal trading on Monday or when the announcement is released to the market, whichever comes first.

The company burned $32 million of cash for FY22 and the cash balance at 31 December 2021 was nearly $55 million. It seems Paradigm wants to solidify its capital base to progress the research initiatives outlined below. 

In its last announcement on Monday, Paradigm reported it will be presenting the results of its drug development to treat the metabolic disease mucopolysaccharidoses (MPS) type I in February next year. 

Paradigm's long-term goal is to develop an injectable form of pentosan polysulfate sodium (PPS) to treat MPS. Historically, PPS has primarily been used to assist with bladder pain.

In addition, Paradigm is researching the use of PPS for a range of other clinical uses, such as treating pain in patients suffering from musculoskeletal disorders. 

Paradigm share price snapshot

The Paradigm share price is up 45% in the last six months and 87% over the past month. It has also gained 4% this year to date.

In contrast, the S&P/ASX 200 Index (ASX: XJO) has declined by 2% across the last six months and 7% year to date, but is up almost 7% in the past month.

The recent rapid rally in the Paradigm share price has been spurred by some positive developments. However, investors should be aware that Paradigm's net loss has been on a downward trend from FY17 to FY21.

The recent momentum has driven Paradigm's market capitalisation to around $450 million.

Motley Fool contributor Raymond Jang has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Capital Raising

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Capital Raising

This ASX mining stock just banked $50 million. So why are its shares falling?

Dateline shares fall after a $50 million raise despite its Colosseum progress.

Read more »

Close-up photo of a human hand with $100 bills offering the money to another human hand.
Capital Raising

Why Magellan shares are rising again after its $20 million raise was swamped

Magellan shares edge higher as investors strongly back the latest capital raising.

Read more »

A man looking at his laptop and thinking.
Materials Shares

Core Lithium shares tumble after $120m capital raising for Finniss restart

It won't be long until the company is producing lithium again.

Read more »

Close-up photo of a human hand with $100 bills offering the money to another human hand.
Capital Raising

Why this ASX healthcare stock has crashed 20% today

The Imugene share price is plunging after announcing a heavily discounted capital raising.

Read more »

A man using a phone shouts and puts his hand out in a stop motion indicating the Yancoal trading halt today
Capital Raising

Magellan requests trading halt ahead of major announcement

Magellan enters a trading halt ahead of a proposed merger and capital raising.

Read more »

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
Capital Raising

Why is this ASX 300 stock crashing 40% today?

Let's see why this stock is crashing deep into the red.

Read more »

A piggy bank is surround by hands preparing to pay coins into the slot, representing a company capital raisingh in asx share price represented by multiple hands all placing coins in a piggy bank
Capital Raising

Santana share price back in trade and down 12%. Here's what just happened

Santana shares tumble 12% after announcing a $130 million capital raise.

Read more »

A miner stands in front of an excavator at a mine site.
Capital Raising

Why this ASX uranium miner's shares are frozen today

This ASX uranium miner is halted as the market waits for further clarity.

Read more »